Vincerx Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VINC Nasdaq 8731 https://vincerx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vincerx Pharma Inc

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 11th, 2023 8:05 pm
Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Apr 19th, 2023 1:05 pm
Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Apr 17th, 2023 5:35 pm
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Apr 17th, 2023 12:00 pm
Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update - Mar 28th, 2023 8:05 pm
Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Mar 14th, 2023 8:35 pm
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely - Feb 27th, 2023 12:55 pm
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference - Feb 6th, 2023 1:00 pm
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236 - Dec 13th, 2022 2:29 pm
Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types - Dec 12th, 2022 9:05 pm
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022 - Dec 11th, 2022 3:05 pm
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Nov 10th, 2022 9:05 pm
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022 - Nov 3rd, 2022 1:05 pm
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update - Aug 11th, 2022 8:05 pm
We Think Vincerx Pharma (NASDAQ:VINC) Needs To Drive Business Growth Carefully - Aug 11th, 2022 1:43 pm
Insider Buying: The Vincerx Pharma, Inc. (NASDAQ:VINC) Founder Just Bought 2.5% More Shares - Jul 1st, 2022 10:03 am
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress - Jun 10th, 2022 12:00 pm
Analysts Cuts Price Target On This Small Cap But Remain Bullish - Jun 7th, 2022 6:11 pm
Small Cap Biotech Vincerx Cuts Third Of Staff - Jun 7th, 2022 12:25 pm
Vincerx Pharma Provides Key Strategic Update - Jun 6th, 2022 8:05 pm